During the congress, one of the topics covered focused on the importance of EGFR TKIs in Advanced NSCLC.

• Apply expert recommendations for frontline therapy for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
• Compare the efficacy and safety of first-generation EGFR TKIs with later-generation EGFR TKIs
• Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding the use of EGFR TKI therapy
• Plan optimal sequencing of EGFR TKIs after considering the available evidence and expert recommendations
• Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC